Literature DB >> 12750523

Tumor response to radiotherapy regulated by endothelial cell apoptosis.

Monica Garcia-Barros1, Francois Paris, Carlos Cordon-Cardo, David Lyden, Shahin Rafii, Adriana Haimovitz-Friedman, Zvi Fuks, Richard Kolesnick.   

Abstract

About 50% of cancer patients receive radiation therapy. Here we investigated the hypothesis that tumor response to radiation is determined not only by tumor cell phenotype but also by microvascular sensitivity. MCA/129 fibrosarcomas and B16F1 melanomas grown in apoptosis-resistant acid sphingomyelinase (asmase)-deficient or Bax-deficient mice displayed markedly reduced baseline microvascular endothelial apoptosis and grew 200 to 400% faster than tumors on wild-type microvasculature. Thus, endothelial apoptosis is a homeostatic factor regulating angiogenesis-dependent tumor growth. Moreover, these tumors exhibited reduced endothelial apoptosis upon irradiation and, unlike tumors in wild-type mice, they were resistant to single-dose radiation up to 20 grays (Gy). These studies indicate that microvascular damage regulates tumor cell response to radiation at the clinically relevant dose range.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750523     DOI: 10.1126/science.1082504

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  446 in total

1.  Impact of stromal sensitivity on radiation response of tumors implanted in SCID hosts revisited.

Authors:  Mónica García-Barros; Tin Htwe Thin; Jerzy Maj; Carlos Cordon-Cardo; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Alpha particles induce apoptosis through the sphingomyelin pathway.

Authors:  Jonathan H Seideman; Branka Stancevic; Jimmy A Rotolo; Michael R McDevitt; Roger W Howell; Richard N Kolesnick; David A Scheinberg
Journal:  Radiat Res       Date:  2011-06-01       Impact factor: 2.841

Review 3.  Chemoattractant receptors as pharmacological targets for elimination of glioma stem-like cells.

Authors:  Xiao-hong Yao; Ying Liu; Keqiang Chen; Wanghua Gong; Ming-yong Liu; Xiu-wu Bian; Ji Ming Wang
Journal:  Int Immunopharmacol       Date:  2011-09-17       Impact factor: 4.932

4.  Diagnosing Lynch syndrome: is the answer in the mouth?

Authors:  H K Roy; H T Lynch
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

5.  Intestinal crypt clonogens: a new interpretation of radiation survival curve shape and clonogenic cell number.

Authors:  S A Roberts; J H Hendry; C S Potten
Journal:  Cell Prolif       Date:  2003-08       Impact factor: 6.831

6.  Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models.

Authors:  Yingjen Jeffrey Wu; Leslie L Muldoon; Dana Thomas Dickey; Seth J Lewin; Csanad G Varallyay; Edward A Neuwelt
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

7.  Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha.

Authors:  Woo-Young Kim; Seung Hyun Oh; Jong-Kyu Woo; Waun Ki Hong; Ho-Young Lee
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 8.  Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer.

Authors:  Young Seok Seo; Mi-Sook Kim; Hyung-Jun Yoo; Won-Il Jang
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

9.  Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization.

Authors:  Daniel J Nolan; Alessia Ciarrocchi; Albert S Mellick; Jaspreet S Jaggi; Kathryn Bambino; Sunita Gupta; Emily Heikamp; Michael R McDevitt; David A Scheinberg; Robert Benezra; Vivek Mittal
Journal:  Genes Dev       Date:  2007-06-15       Impact factor: 11.361

10.  Thermal imaging as a tool for evaluating tumor treatment efficacy.

Authors:  Oshrit A Hoffer; Merav A Ben-David; Eyal Katz; Dana Zoltnik Kirshenabum; Dror Alezra; Yair Zimmer; Itzhak Kelson; Israel Gannot
Journal:  J Biomed Opt       Date:  2018-05       Impact factor: 3.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.